Maxime Verhoeven

Published in Rheumatol Ther. 2020;7:837-850 H.R. Gosselt 1,2 M.M.A. Verhoeven 3 M.C.F.J. de Rotte 4 S.M.F. Pluijm 5 I.B. Muller 1 G. Jansen 6 J. Tekstra 3 M. Bulatović-Ćalasan 7 S.G. Heil 2 F.P.J.G. Lafeber 3 J.M.W. Hazes 8* R. de Jonge 1* * JMWH and RdJ contributed equally to this manuscript as senior authors. 1 Department of Clinical Chemistry, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; 2 Department of Clinical Chemistry, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands; 3 Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, the Netherlands; 4 Department of Clinical Chemistry, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands. 5 Department of Paediatric Oncology, Prinses Máxima Centre for Paediatric Oncology, Utrecht, the Netherlands; 6 Amsterdam Rheumatology and Immunology Center, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; 7 Department of Internal Medicine, University Medical Center Utrecht, Utrecht, the Netherlands; 8 Department of Rheumatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands. Chapter 4: Validation of a prognostic multivariable prediction model for insufficient clinical response to methotrexate in early rheumatoid arthritis and its clinical application in Evidencio.